These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22187250)

  • 21. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Luteal Phase Ovarian Stimulation May Improve Oocyte Retrieval and Oocyte Quality in Poor Ovarian Responders Undergoing In Vitro Fertilization: Preliminary Results from a Single-Center Prospective Pilot Study.
    Lin LT; Vitale SG; Chen SN; Wen ZH; Tsai HW; Chern CU; Tsui KH
    Adv Ther; 2018 Jun; 35(6):847-856. PubMed ID: 29869107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction-intrauterine insemination to in vitro fertilization conversions, independent of age and estradiol level on the day of human chorionic gonadotropin administration.
    Quaas AM; Missmer SA; Ginsburg ES
    Fertil Steril; 2010 Feb; 93(2):605-8. PubMed ID: 19324340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?
    Orvieto R; Nahum R; Rabinson J; Ashkenazi J; Anteby EY; Meltcer S
    Fertil Steril; 2009 Apr; 91(4 Suppl):1522-5. PubMed ID: 18851846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation.
    Kolibianakis E; Zikopoulos K; Camus M; Tournaye H; Van Steirteghem A; Devroey P
    Hum Reprod; 2004 Nov; 19(11):2545-9. PubMed ID: 15471941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The number of oocytes retrieved during IVF: a balance between efficacy and safety.
    Magnusson Å; Källen K; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2018 Jan; 33(1):58-64. PubMed ID: 29136154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study.
    Revelli A; Chiado' A; Guidetti D; Bongioanni F; Rovei V; Gennarelli G
    J Assist Reprod Genet; 2012 Sep; 29(9):869-75. PubMed ID: 22644636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of follicle-flushing during oocyte collection on embryo development of in-vitro fertilization.
    Zhu LH; Ni XB; Lin F; Xu ZP; Fang JS; Zhang NY
    Reprod Biol Endocrinol; 2019 Dec; 17(1):106. PubMed ID: 31805966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inadvertent recombinant human follicle stimulating hormone bolus instead of human chorionic gonadotrophin leads to the retrieval of competent oocytes in IVF program.
    Bianchi V; Dal Prato L; Maccolini A; Mazzone S; Borini A
    Fertil Steril; 2009 Nov; 92(5):1747.e1-3. PubMed ID: 19732874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Smoothing Gan Reinforcing Shen Method Adjuvantly Treated Poor Response of Diminished Ovari- an Reserve Patients in in vitro Fertilization and Embryo Transfer: a Clinical Study].
    Zhang Z; Zhang XH; He TY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Oct; 35(10):1170-4. PubMed ID: 26677665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The significance of antral follicle size prior to stimulation in predicting ovarian response in a multiple dose GnRH antagonist protocol.
    Lai Q; Chen C; Zhang Z; Zhang S; Yu Q; Yang P; Hu J; Wang CY
    Int J Clin Exp Pathol; 2013; 6(2):258-66. PubMed ID: 23330011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
    Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
    Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the number of retrieved oocytes on IVF outcomes: oocyte maturation, fertilization, embryo quality and implantation rate.
    Jamil M; Debbarh H; Kabit A; Ennaji M; Zarqaoui M; Senhaji WR; Hissane M; Saadani B; Louanjli N; Cadi R
    Zygote; 2023 Feb; 31(1):91-96. PubMed ID: 36533391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
    Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
    Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which ovarian stimulation parameters influence the number and proportion of mature oocytes retrieved in IVF cycles?
    Sethi A; Singh N; Patel G
    J Assist Reprod Genet; 2021 Nov; 38(11):3061-3062. PubMed ID: 34623543
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up.
    Kolibianakis E; Bourgain C; Albano C; Osmanagaoglu K; Smitz J; Van Steirteghem A; Devroey P
    Fertil Steril; 2002 Nov; 78(5):1025-9. PubMed ID: 12413988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.